Life Sciences Investment

Ian Sollom Excerpts

Thursday 11th September 2025 Commons Chamber

[Mr Speaker]

I call the Liberal Democrat spokesperson.

[Ian Sollom (St Neots and Mid Cambridgeshire) (LD)]

I welcome the Minister to his place. It is incredibly disappointing that MSD has pulled out of this billion-pound investment in the UK, including the loss of more than 100 jobs in important life sciences infrastructure. However, this has been on the cards for some time, and the warnings to Government have fallen on deaf ears. Earlier this year, AstraZeneca also cancelled planned upgrades to its production, and Novartis has described the UK as “largely uninvestable”. One pharmaceutical company reducing its UK operations is a problem, but there is a worrying trend that threatens a crisis in the sector.

The UK is becoming less and less attractive to the life sciences industry, and with good reason. First, the Budget saw huge rises in costs to all businesses, including through Labour’s jobs tax. Secondly, there has been a notable lack of investment across the life sciences sector, including in job creation, critical skills and creating a commercial environment that can compete internationally. The Lib Dems continue to call for the Government to make research and development investment 3.5% of GDP, and the life sciences would be a key focus. That would be coupled with extra support for academic institutions to commercialise research. How do the Government plan to restore confidence among pharmaceutical companies that the UK is a competitive place for research and development and manufacturing?

[Ian Murray]

I am grateful to the hon. Gentleman for raising those points. It is important to lay out to the public and to the House that MSD will continue to employ 1,600 people and be a key part of the life sciences sector. There are many companies that are investing in this country—Moderna, BioNTech, Isomorphic Labs—and in my own constituency, Roslin CT is expanding at such a great pace that it cannot keep up with the amount of space and the wet lab facilities it requires. Those are all the challenges that we have to try and deal with.

I gently say to the hon. Gentleman: the second sentence of his contribution was about the national insurance increases for employers and the fourth was about spending more money on R&D and life sciences. They cannot both be true. If we want to spend money on our priorities—political parties will have different priorities—we have to raise that money. We cannot have it both ways. The message to the industry is: this is the best place in the world to invest. Bring your investment here and this Government back you through an industrial strategy and a life sciences sector plan.